Schwartz Ann G, Wenzlaff Angela S, Prysak Geoffrey M, Murphy Valerie, Cote Michele L, Brooks Sam C, Skafar Debra F, Lonardo Fulvio
Population Studies and Prevention Program, Karmanos Cancer Institute, 110 E Warren Ave, Detroit, MI 48201, USA.
J Clin Oncol. 2007 Dec 20;25(36):5785-92. doi: 10.1200/JCO.2007.13.3975.
Estrogen receptor (ER) expression in lung tumors suggests that estrogens may play a role in the development of lung cancer. We evaluated the role of hormone-related factors in determining risk of non-small-cell lung cancer (NSCLC) in women. We also evaluated whether risk factors were differentially associated with cytoplasmic ER-alpha and/or nuclear ER-beta expression-defined NSCLC in postmenopausal women.
Population-based participants included women aged 18 to 74 years diagnosed with NSCLC in metropolitan Detroit between November 1, 2001 and October 31, 2005. Population-based controls were identified through random digit dialing, matched to patient cases on race and 5-year age group. Interview data were analyzed for 488 patient cases (241 with tumor ER results) and 498 controls.
Increased duration of hormone replacement therapy (HRT) use in quartiles was associated with decreased risk of NSCLC in postmenopausal women (odds ratio = 0.88; 95% CI, 0.78 to 1.00; P = .04), adjusting for age, race, pack-years, education, family history of lung cancer, current body mass index, years exposed to second-hand smoke in the workplace, and obstructive lung disease history. Among postmenopausal women, ever using HRT, increasing HRT duration of use in quartiles, and increasing quartiles of estrogen use were significant predictors of reduced risk of NSCLC characterized as ER-alpha and/or ER-beta positive. None of the hormone-related variables were associated with nuclear ER-alpha- or ER-beta-negative NSCLC.
These findings suggest that postmenopausal hormone exposures are associated with reduced risk of ER-alpha- and ER-beta-expressing NSCLC. Understanding tumor characteristics may direct development of targeted treatment for this disease.
肺肿瘤中雌激素受体(ER)的表达表明雌激素可能在肺癌发展中起作用。我们评估了激素相关因素在确定女性非小细胞肺癌(NSCLC)风险中的作用。我们还评估了绝经后女性中危险因素是否与细胞质ER-α和/或细胞核ER-β表达定义的NSCLC存在差异关联。
基于人群的参与者包括2001年11月1日至2005年10月31日期间在底特律大都市被诊断为NSCLC的18至74岁女性。通过随机数字拨号确定基于人群的对照,按种族和5岁年龄组与患者病例匹配。对488例患者病例(241例有肿瘤ER结果)和498例对照的访谈数据进行了分析。
按四分位数分组,激素替代疗法(HRT)使用时间延长与绝经后女性NSCLC风险降低相关(优势比=0.88;95%可信区间,0.78至1.00;P=0.04),对年龄、种族、吸烟包年数、教育程度、肺癌家族史、当前体重指数、工作场所二手烟暴露年限和阻塞性肺病病史进行了校正。在绝经后女性中,曾经使用HRT、按四分位数分组HRT使用时间增加以及雌激素使用四分位数增加是ER-α和/或ER-β阳性NSCLC风险降低的显著预测因素。没有一个激素相关变量与细胞核ER-α或ER-β阴性NSCLC相关。
这些发现表明绝经后激素暴露与ER-α和ER-β表达型NSCLC风险降低相关。了解肿瘤特征可能指导针对该疾病的靶向治疗的开发。